Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic

• Published in: Current oncology (Toronto) 2023-08, Vol.30 (9), p.7852-7859
• Main Authors: Pang, Steph A, Elkrief, Arielle, Capella, Mariana Pilon, Miller, Jr, Wilson H
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Animals; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents, Immunological - adverse effects; B cells; Bacterial pneumonia; camu camu; Cancer; Care and treatment; Case Report; Colitis; Development and progression; Female; Humans; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immune response; Male; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Melanoma, Cutaneous Malignant; Metastasis; Mice; microbiome; Microbiota (Symbiotic organisms); Neoplasm Recurrence, Local; Nivolumab - therapeutic use; Pharmaceutical industry; Pneumonia; prebiotic; Prevention; rechallenge; T cells
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol30090570

Camu camu (CC) is a prebiotic that selectively stimulates growth and activity of beneficial gut microbiota. Work in murine models demonstrated that castalagin, the active compound in CC, preferentially binds to beneficial gut microbiome bacteria, promoting a stronger CD8+T cell anti-cancer response. We present two patients with metastatic melanoma whose cancer progressed on immune checkpoint inhibitors (ICIs) and developed clinically significant immune-related adverse events (irAEs). They were rechallenged with ICIs in combination with CC. The first patient is a 71-year-old woman with metastatic melanoma, whose ICI treatment was complicated by immune-related pneumonitis and colitis. Upon progression on maintenance nivolumab, CC was added to nivolumab, leading to a near complete response (CR). The second patient is a 90-year-old man with recurrent unresectable melanoma, treated with nivolumab, complicated by immune-related rash and diabetes. He developed new subcutaneous calf lesions and a metastatic popliteal lymph node. CC was added to nivolumab. One month later, the patient experienced a CR. Both patients have been on nivolumab and CC with durable responses for more than a year, with minimal irAEs. These two cases suggest that CC may modulate the microbiome, synergizing with ICIs to produce deep, durable responses with minimal irAEs.